查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837137

按給藥途徑、治療方法、結核病類型和分銷管道分類的結核病藥物市場 - 全球預測 2025-2032

Tuberculosis Drugs Market by Route Of Administration, Treatment Regimen, Tuberculosis Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年結核病藥物市場規模將成長至 33.8 億美元，複合年成長率為 6.46%。

主要市場統計數據
基準年2024年 20.4億美元
預計2025年 21.8億美元
預測年份：2032年 33.8億美元
複合年成長率（%） 6.46%

簡潔、策略性地介紹了影響結核病藥物的臨床、監管和商業性背景以及製定領導者所需做出的決策。

本執行摘要總結了當代影響結核病藥物因應的動態，並組裝了高階領導者必須回答的策略問題。它匯集了臨床進展、監管變革、供應鏈現狀、付款方和提供者的行為以及競爭定位，為董事會層面的討論和商業規劃提供了簡潔的參考。本書面向相關人員明確發展動能、風險集中點以及臨床實務中治療模式的演變。

本書首先強調了結核病對全球公共衛生的持續重要性，以及重要的治療方法創新。近年來，臨床醫生和國家計畫越來越重視針對多種抗藥性疾病的短期全口服治療方案，而診斷技術的改進也使得早期發現和更精準的治療選擇成為可能。這些臨床變革，加上供應鏈依賴性、價格壓力和監管調整，為製造商、經銷商和臨床網路帶來了機會和必要性。

本介紹涵蓋了轉型轉變、關稅相關影響、細分和區域影響、競爭情報、可操作的建議和調查方法，目的是為決策者提供平衡臨床現實與商業性執行的綜合觀點。

最近的臨床突破、診斷整合和採購現代化如何從根本上重塑結核病藥物治療途徑和商業策略

由於臨床創新、治療指南修訂以及技術驅動的診斷技術，結核病藥物治療格局正在發生重大變化。全口服方案的採用和短期療程方案的整合正開始改變許多高負擔地區的處方習慣，新型藥物的出現也正在改變多重抗藥性結核病的臨床治療路徑。同時，對以病人為中心的醫療服務和分散式治療的日益重視，促使支付方和衛生系統優先考慮能夠減少住院率和提高依從性的方案。

這些治療方法進展伴隨著法律規範和採購慣例的變化，從而促進了針對未滿足需求的藥物的更快核准。治療產品製造商和臨床專案經理必須應對這樣一個環境：真實世界證據和專案數據在報銷討論和國家治療政策更新中的重要性日益凸顯。此外，對照護現場和分子診斷的投資正在改善病例檢測，並帶來更具針對性的治療方法方案，從而在診斷能力與特定藥物方案需求之間建立緊密的聯繫。

總體而言，這些競爭變化正在重塑競爭動態，迫使供應商透過處方集獲取、低溫運輸和配送支援等服務，以及將臨床試驗結果轉化為規模化應用的夥伴關係關係來差異化競爭。最終將形成一個更整合的生態系統，其中治療價值不僅取決於療效，還取決於交付模式、依從性支持以及與國家結核病控制重點的一致性。

評估 2025 年美國關稅如何重塑整個結核病藥物供應網路的供應鏈彈性、籌資策略和購買行為

2025年美國實施的關稅和貿易措施，正在對支持結核病治療供應的全球醫藥供應鏈和採購管道造成顯著的摩擦。許多成品藥和原料藥是透過複雜的國際網路購買的。徵收關稅和相關管控要求將增加到岸成本，改變供應商的選擇標準，並延長關鍵投入的前置作業時間。這些影響將波及採購週期、庫存政策以及製造商、經銷商和公共衛生採購商之間的合約談判。

為此，製造商和國家專案正在審查籌資策略，透過近岸外包和替代原料藥供應商的資格認證來加速供應商多元化，以降低單一來源風險。付款人和大型機構採購商正在審查合約條款和庫存緩衝，以在應對價格壓力的同時保持供應的連續性。監管機構和海關部門也在製定程序指南，以加快基本藥物的供應，但關稅政策的不確定性仍可能鼓勵囤積和保守採購，從而扭曲正常的採購模式。

對商業相關人員，關稅環境凸顯了營運敏捷性和服務成本最佳化的策略重要性。能夠重組供應鏈、在地化關鍵製造流程並展示彈性通路的公司將減少貿易政策波動的影響。同時，公共衛生計畫必須在財務管理和以病人為中心的服務交付之間取得平衡，權衡短期成本與長期需求（例如持續照護和計畫成果）。

詳細的細分分析揭示了給藥途徑、治療方案的複雜性、疾病概況和分銷管道如何相互作用，從而塑造您的產品和服務策略

細分洞察揭示了臨床用例和通路之間的差異化動態，為產品定位、服​​務模式和商業化計劃提供了啟示。根據給藥途徑，此領域分為注射療法和口服療法。隨著臨床醫生傾向於縮短住院時間和提高患者依從性，口服療法將繼續擴展，而注射療法將在特定臨床情況和同情用藥場景中保持一席之地。根據治療方法，相關人員必須處理個人化治療方案與標準化長期和短期治療方案的共存。雖然個人化治療方案需要靈活的供應和診斷聯繫，但標準化的長期和短期方案可受益於簡化的採購和專案部署。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 貝達喹啉和德拉馬尼的擴大獲取計畫加速了耐多藥結核病高負擔國家的治療選擇
  • 提高抗藥性和藥物敏感結核病患者對基於 pretomanid 的較短療程治療方案的依從性
  • 開發針對持續性結核分枝桿菌的新型Oxazolidinone衍生物以縮短治療週期
  • 整合全基因組定序和藥物敏感性測試實現個人化多模態結核病治療
  • 客製化固定劑量組合產品的普及，以提高兒童結核病治療的劑量準確性和依從性
  • 監管機構核准第二代硝基咪唑化合物，旨在克服結核分枝桿菌菌株的抗藥性

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 依給藥途徑分類的結核病藥物市場

  • 注射
  • 口服

9. 結核病藥物市場（治療方法）

  • 個人化治療方案
  • 長距離路線
  • 短期課程

第 10 章：結核病藥物市場（依結核病類型分類）

  • 肺外
  • 肺

第 11 章結核病藥物市場（依分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第12章結核病藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章結核病藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章各國結核病藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Johnson & Johnson
    • Lupin Limited
    • Cipla Limited
    • Viatris Inc
    • Sun Pharmaceutical Industries Limited
    • Otsuka Pharmaceutical Co., Ltd.
    • Dr. Reddy's Laboratories Limited
    • Teva Pharmaceutical Industries Limited
    • Glenmark Pharmaceuticals Limited
    • F. Hoffmann-La Roche Ltd
Product Code: MRR-03252A5F9277

The Tuberculosis Drugs Market is projected to grow by USD 3.38 billion at a CAGR of 6.46% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.04 billion
Estimated Year [2025] USD 2.18 billion
Forecast Year [2032] USD 3.38 billion
CAGR (%) 6.46%

A concise and strategic introduction framing the clinical, regulatory, and commercial contexts shaping tuberculosis drugs and the decisions leaders must make

This executive summary synthesizes contemporary dynamics shaping pharmaceutical responses to tuberculosis and frames the strategic questions that senior leaders must answer. The content aggregates clinical advances, regulatory shifts, supply chain realities, payer and provider behaviors, and competitive positioning to create a concise reference that supports board-level discussions and commercial planning. It is written for stakeholders who require clarity on where momentum exists, where risk concentrations lie, and how treatment paradigms are evolving in clinical practice.

The opening context highlights the sustained global public health imperative posed by tuberculosis alongside significant therapeutic innovation. Over recent years, clinicians and national programs have increasingly emphasized shorter, all-oral regimens for many forms of drug-resistant disease, while diagnostics improvements are enabling earlier detection and more precise treatment selection. These clinical shifts intersect with supply chain dependencies, pricing pressures, and regulatory adaptations, creating both opportunities and imperatives for manufacturers, distributors, and clinical networks.

This introduction positions the subsequent sections to examine transformative shifts, tariff-related impacts, segmentation- and region-specific implications, competitor intelligence, actionable recommendations, and the methodology underpinning the research. The aim is to equip decision-makers with an integrated perspective that balances clinical realities with commercial execution.

How recent clinical breakthroughs, diagnostic integration, and procurement modernization are fundamentally reshaping treatment pathways and commercial strategies for tuberculosis therapeutics

The landscape for tuberculosis therapeutics is undergoing transformative shifts driven by clinical innovation, revised treatment guidelines, and technology-enabled diagnostics. Adoption of all-oral regimens and the consolidation of shorter-course options have begun to change prescribing habits in many high-burden settings, while the emergence of novel agents has altered clinical pathways for multidrug-resistant disease. At the same time, increased emphasis on patient-centered care and decentralization of treatment delivery is prompting payers and health systems to prioritize regimens that reduce hospitalization and improve adherence.

These therapeutic advances are accompanied by changes in regulatory frameworks and procurement practices that favor accelerated pathways for drugs addressing unmet needs. Manufacturers and clinical program managers must navigate an environment where real-world evidence and programmatic data carry rising weight in reimbursement discussions and national treatment policy updates. Additionally, investment in point-of-care and molecular diagnostics is improving case detection and enabling more targeted therapy selection, creating stronger linkages between diagnostic capacity and demand for specific drug regimens.

Collectively, these shifts are reshaping competitive dynamics, forcing suppliers to differentiate through formulary access, service offerings such as cold chain and distribution support, and partnerships that connect clinical trial outcomes to implementation at scale. The result is a more integrated ecosystem in which therapeutic value is determined not only by efficacy but also by delivery model, adherence support, and alignment with national TB control priorities.

Assessment of how 2025 tariff measures in the United States are reshaping supply chain resilience, sourcing strategies, and procurement behavior across tuberculosis drug supply networks

The introduction of tariffs and trade measures in the United States during 2025 is creating measurable friction across global pharmaceutical supply chains and procurement channels that support tuberculosis drug availability. Many finished pharmaceuticals and active pharmaceutical ingredients are sourced through complex international networks; the imposition of duties and related administrative requirements increases landed costs, alters supplier selection calculus, and extends lead times for critical inputs. These effects ripple through procurement cycles, inventory policies, and contractual negotiations between manufacturers, distributors, and public health purchasers.

In response, manufacturers and national programs are reassessing sourcing strategies and accelerating supplier diversification, including nearshoring and qualifying alternative API suppliers to mitigate single-source exposure. Payers and large institutional purchasers are revisiting contractual terms and inventory buffers to preserve continuity of supply while managing price pressures. Regulatory agencies and customs authorities are also evolving procedural guidance to expedite essential medicines, but uncertainty in tariff policy can still incentivize stockpiling or conservative procurement that distorts normal purchasing patterns.

For commercial stakeholders, the tariff environment increases the strategic importance of operational agility and cost-to-serve optimization. Firms that can reconfigure supply chains, localize critical manufacturing steps, and demonstrate resilient distribution channels will reduce exposure to trade-policy volatility. Meanwhile, public health programs will need to weigh short-term cost implications against the longer-term imperatives of treatment continuity and programmatic outcomes, balancing fiscal stewardship with patient-centered service delivery.

Deep segmentation analysis revealing how route of administration, regimen complexity, disease presentation, and distribution channels interact to shape product and service strategies

Segmentation insight reveals differentiated dynamics across clinical use cases and distribution pathways, with implication for product positioning, service models, and commercialization plans. Based on route of administration, the landscape is divided between injectable and oral therapies, where oral regimens continue to expand as clinicians favor reduced hospitalization and improved patient adherence, while injectable options retain niche roles for specific clinical circumstances and compassionate-use scenarios. Based on treatment regimen, stakeholders must navigate the coexistence of individualized regimen approaches alongside long-course and short-course standardized regimens; individualized regimens require flexible supply and diagnostic linkage, whereas standardized long-course and short-course options benefit from streamlined procurement and programmatic rollout.

Based on tuberculosis type, the clinical and logistical requirements differ substantially between extrapulmonary and pulmonary presentations, with extrapulmonary disease often necessitating longer diagnostic workups and multidisciplinary care, and pulmonary disease remaining the major driver of transmission-control strategies. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy pathways each present distinct commercialization considerations: hospital pharmacy channels demand integration with inpatient formularies and clinical stewardship programs, online pharmacy channels require robust cold chain and regulatory compliance for cross-border delivery, and retail pharmacy channels depend on community-level prescribing patterns and patient access programs.

These segmentation axes interact: for example, the adoption of short-course oral regimens for pulmonary TB may shift demand toward retail and online distribution for outpatient management, while individualized regimens for extrapulmonary or drug-resistant cases will concentrate demand in hospital pharmacy and specialty distribution channels. Effective commercial strategies will therefore align product portfolios and service propositions with route-of-administration preferences, regimen complexity, disease presentation, and channel-specific operational requirements.

Regional intelligence describing how epidemiology, health system capacity, procurement modalities, and manufacturing footprints uniquely shape tuberculosis drug access and implementation

Regional dynamics underscore how epidemiology, health system capacity, and procurement practices create distinct contexts for deployment and commercialization of tuberculosis therapeutics. In the Americas, national programs and private-sector providers coexist with diversified manufacturing footprints, and payer engagement focuses on balancing public health imperatives with budgetary constraints; partnerships between public procurement agencies and regional manufacturers influence access strategies. In Europe, Middle East & Africa, heterogeneity is significant: high-income European systems concentrate on novel treatment adoption and integration with diagnostics, while many countries within the Middle East & Africa region face infrastructural constraints that prioritize simple, resilient regimens and supply chains able to operate under logistical stress.

In the Asia-Pacific region, where a substantial burden of tuberculosis persists in several countries, the interplay of local manufacturing capabilities, large-scale public procurement programs, and evolving treatment guidelines drives rapid implementation of newer regimens in some settings while others continue incremental transitions. Regional procurement mechanisms, donor-funded programs, and public-private partnerships remain important levers to accelerate access, but local regulatory harmonization and capacity building for diagnostics are often prerequisites for widescale adoption.

Across all regions, tailored strategies that account for national policy environments, distribution network maturity, and clinician practice patterns will be essential. Commercial and public health actors should calibrate engagement models to regional priorities, investing in diagnostic linkage, training, and supply-chain strengthening where needed to translate therapeutic potential into measurable patient benefit.

Analysis of competitive positioning and partnership models among manufacturers, generic producers, and service-oriented entrants that determine access pathways and commercialization success

Competitive and partnership dynamics among pharmaceutical firms, generic manufacturers, and specialty suppliers continue to shape access pathways and therapeutic mix. Established producers of foundational anti-tuberculosis agents maintain critical relationships with national procurement agencies and hospital formularies, which creates barriers to rapid displacement but also opportunities for differentiated offerings that reduce total cost of care or simplify logistics. At the same time, innovators bringing newer oral regimens and novel agents are pursuing strategic alliances with diagnostic companies, non-governmental implementers, and contract manufacturers to accelerate inclusion in national treatment guidelines and secure supply commitments.

Generic manufacturers play a central role in expanding geographic access, particularly through licensed production and voluntary licensing frameworks that enable broader distribution in low- and middle-income countries. Specialty suppliers and contract manufacturing organizations are increasingly important partners for scaling production of newer compounds and ensuring compliance with international quality standards. Meanwhile, service-oriented entrants that package therapeutics with adherence support tools, digital monitoring platforms, and supply-chain visibility solutions are creating competitive differentiation beyond the core molecule.

For incumbent and new entrants alike, winning in this environment requires a dual focus on clinical evidence generation and implementation science. Firms that can demonstrate real-world effectiveness, safety across diverse populations, and cost-and-care pathway advantages will gain traction with payers and national programs. Strategic licensing, targeted R&D investments, and flexible commercial models that accommodate both programmatic procurement and private-sector channels will be decisive features of successful company strategies.

Actionable recommendations for industry leaders to align diagnostics, diversify supply chains, and deploy integrated service models that secure continuity and accelerate appropriate regimen adoption

Leaders across industry, public health programs, and procurement agencies should adopt a set of practical actions to navigate clinical evolution, supply chain turbulence, and policy uncertainty. First, prioritize integration between diagnostics and therapeutics to ensure regimen selection aligns with rapid and accurate case detection; investments in molecular diagnostics and training will improve regimen appropriateness and reduce downstream costs associated with treatment failure. Second, diversify supplier networks for critical APIs and finished dosage forms while building conditional local manufacturing options where feasible to reduce exposure to trade-policy disruptions and single-source dependencies.

Third, design commercial offerings that combine product access with implementation support, leveraging digital adherence tools, patient education, and tailored service bundles to enhance uptake and real-world outcomes. Fourth, engage proactively with regulatory authorities and national programs to provide robust real-world evidence and post-marketing safety data that can accelerate guideline inclusion. Finally, adapt contracting and pricing approaches to accommodate public-sector procurement cycles and donor-funded programs, while preserving commercial viability through tiered access models and outcome-linked agreements.

Taken together, these steps constitute a pragmatic roadmap to sustain supply continuity, accelerate appropriate regimen adoption, and align commercial execution with public health objectives. Organizations that operationalize these recommendations will be better positioned to deliver clinical value and maintain resilient operations amid evolving policy and clinical landscapes.

Transparent and reproducible research methodology combining stakeholder interviews, literature synthesis, supply-chain mapping, and scenario analysis to generate actionable intelligence

This research synthesizes primary and secondary intelligence through a structured methodology designed to produce actionable insights while preserving analytical rigor. The approach combined targeted stakeholder interviews with clinicians, procurement officials, and senior executives across manufacturers and distribution channels, supplemented by a systematic review of peer-reviewed clinical literature, regulatory guidance, and programmatic reports up to mid-2024. Data triangulation was applied to reconcile differing perspectives and identify persistent themes across geographies and stakeholder types.

Qualitative findings were contextualized by supply-chain mapping exercises and scenario analysis to assess operational sensitivities to trade-policy changes and sourcing disruptions. Case studies illustrating successful regimen adoption and implementation were selected to highlight transferable lessons and operational enablers. The research also incorporated a review of clinical guideline updates and regulatory approvals that materially affect treatment pathways, ensuring alignment between clinical evidence and commercial implications.

Throughout, ethical standards for interview consent and data confidentiality were maintained, and limitations are transparently acknowledged where public data are incomplete or where evolving clinical evidence could alter strategic implications. The methodology emphasizes reproducibility and practical relevance, enabling stakeholders to adapt the analytical framework to their internal decision processes.

Concluding synthesis emphasizing the imperative for integrated clinical, supply-chain, and commercial approaches to translate therapeutic advances into sustained patient access

In conclusion, the tuberculosis therapeutics landscape is at an inflection point where clinical innovation, diagnostics integration, and supply-chain resilience collectively determine which therapies will achieve routine use. Shorter, all-oral regimens and targeted use of novel agents offer substantive benefits for patient adherence and programmatic delivery, but their impact depends on reliable diagnostics, secure supply chains, and pragmatic procurement approaches. Trade-policy developments and tariff measures introduce a new layer of operational risk that organizations must actively mitigate through supplier diversification and strategic localization.

Companies that pair clinical credibility with implementation capabilities-such as adherence support, diagnostic linkage, and flexible distribution models-will be best positioned to translate therapeutic advancements into sustained patient access. Public health programs and donors should continue to prioritize investments that strengthen the diagnostic-to-treatment continuum and support procurement mechanisms that preserve continuity of care. The path forward requires collaborative approaches that align commercial incentives with public health objectives to ensure that advances in therapy translate into better outcomes for patients living with tuberculosis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of bedaquiline and delamanid access programs in high-burden MDR-TB countries accelerating treatment options
  • 5.2. Adoption of shorter pretomanid-based regimens for both drug-resistant and drug-sensitive tuberculosis improving compliance
  • 5.3. Development of novel oxazolidinone derivatives targeting persistent tuberculosis bacteria to reduce therapy length
  • 5.4. Integration of whole-genome sequencing into drug susceptibility testing to personalize multimodal tuberculosis treatment
  • 5.5. Surge in fixed-dose combination formulations tailored for pediatric tuberculosis to enhance dosing accuracy and adherence
  • 5.6. Regulatory approvals of second-generation nitroimidazole compounds aimed at overcoming drug resistance in TB strains

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Tuberculosis Drugs Market, by Route Of Administration

  • 8.1. Injectable
  • 8.2. Oral

9. Tuberculosis Drugs Market, by Treatment Regimen

  • 9.1. Individualized Regimen
  • 9.2. Long Course
  • 9.3. Short Course

10. Tuberculosis Drugs Market, by Tuberculosis Type

  • 10.1. Extrapulmonary
  • 10.2. Pulmonary

11. Tuberculosis Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Tuberculosis Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Tuberculosis Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Tuberculosis Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Johnson & Johnson
    • 15.3.2. Lupin Limited
    • 15.3.3. Cipla Limited
    • 15.3.4. Viatris Inc
    • 15.3.5. Sun Pharmaceutical Industries Limited
    • 15.3.6. Otsuka Pharmaceutical Co., Ltd.
    • 15.3.7. Dr. Reddy's Laboratories Limited
    • 15.3.8. Teva Pharmaceutical Industries Limited
    • 15.3.9. Glenmark Pharmaceuticals Limited
    • 15.3.10. F. Hoffmann-La Roche Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. TUBERCULOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. TUBERCULOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TUBERCULOSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INDIVIDUALIZED REGIMEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INDIVIDUALIZED REGIMEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INDIVIDUALIZED REGIMEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INDIVIDUALIZED REGIMEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INDIVIDUALIZED REGIMEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INDIVIDUALIZED REGIMEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LONG COURSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LONG COURSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LONG COURSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LONG COURSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LONG COURSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LONG COURSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SHORT COURSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SHORT COURSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SHORT COURSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SHORT COURSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SHORT COURSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SHORT COURSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY EXTRAPULMONARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY EXTRAPULMONARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY EXTRAPULMONARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY EXTRAPULMONARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY EXTRAPULMONARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY EXTRAPULMONARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PULMONARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PULMONARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PULMONARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PULMONARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PULMONARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PULMONARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 77. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 79. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 81. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 83. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 84. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 88. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 90. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 92. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 94. NORTH AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 98. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 100. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 104. LATIN AMERICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 118. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 119. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 120. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 121. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 124. EUROPE TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 128. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 130. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. MIDDLE EAST TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 138. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 139. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 140. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 141. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 144. AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 160. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 161. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 162. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 163. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. ASEAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 171. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 172. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 173. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. GCC TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPEAN UNION TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 187. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 190. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 191. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 192. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 193. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. BRICS TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 200. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 201. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 202. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 203. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. G7 TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 212. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 213. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. NATO TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 222. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 223. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 230. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 231. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 235. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 238. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 239. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 245. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 246. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 247. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 262. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 263. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 270. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 271. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 276. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 277. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 278. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 279. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 286. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 287. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 292. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 293. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 294. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 295. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 300. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 301. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 302. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 303. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 310. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 311. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 314. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 315. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 316. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 317. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 318. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 319. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 322. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 323. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 324. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 325. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
  • TABLE 326. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY TREATMENT REGIMEN, 2025-2032 (USD MILLION)
  • TABLE 327. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY TUBERCULOSIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 332. SOUTH KOREA TUBERCULOSI